Development and Investigation of Assays For Cardiovascular Risk Assessment

直接检测HDL-C和LDL-C的方法不需要对脂蛋白进行物理分离，在常规临床实验室检测中具有许多实际优点，目前已被广泛应用。然而，根据我们之前的工作，我们发现，它们通常会产生与金标准方法（包括超离心）有很大不同的结果。在过去的一年里，我们通过评估在心血管风险评估中计算非hdl - c的分析错误的影响来扩展这项工作。结果表明，对于患有血脂异常的患者，使用直接HDL-C测定非HDL-C优于使用直接LDL-C将患者划分为心血管风险类别。我们还发现，对于一些直接的HDL-C测定，用于计算LDL-C的Friedewald方程的替代方案与超离心具有更好的对应关系。我们还完成了一项研究，目前正在分析比较载脂蛋白ob和LDL-P的数据，通过核磁共振测量，预测MESA人群的心血管事件。

Direct HDL-C and LDL-C methods, which do not require the physical separation of lipoproteins, offer many practical advantages for routine clinical laboratory testing and are now widely utilized. Based on our previous work, we found, however, that they often yield results that substantially differ by the gold standard method, involving ultracentrifugation. In the past year, we have extended this work by assessing the impact of analytical errors in the calculation of Non-HDL-C in cardiovascular risk assessment. The results show that for patients with a dyslipidemia that Non-HDL-C, using a direct HDL-C assay, was superior to using a direct LDL-C in categorizing patients into cardiovascular risk categories. We also found that for some direct HDL-C assays that alternatives to the Friedewald equation for calculating LDL-C showed better correspondence to ultracentrifugation. We also completed a study and are now analyzing the data comparing apoB to LDL-P, as measured by NMR, in predicting cardiovascular events in the MESA population.